Last reviewed · How we verify
Palonosetron (Group P)
Palonosetron is a highly selective 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract to prevent nausea and vomiting.
Palonosetron is a highly selective 5-HT3 receptor antagonist that blocks serotonin signaling in the chemoreceptor trigger zone and gastrointestinal tract to prevent nausea and vomiting. Used for Chemotherapy-induced nausea and vomiting (CINV) prevention, Post-operative nausea and vomiting (PONV) prevention.
At a glance
| Generic name | Palonosetron (Group P) |
|---|---|
| Also known as | antiemetic |
| Sponsor | University of Malaya |
| Drug class | 5-HT3 receptor antagonist |
| Target | 5-HT3 receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology, Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Palonosetron binds with high affinity and selectivity to 5-hydroxytryptamine type 3 (5-HT3) receptors, which are located on vagal afferents in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By antagonizing these receptors, it prevents the emetic signal cascade triggered by chemotherapy, radiation, or post-operative conditions. It has a longer half-life and greater receptor binding affinity compared to earlier-generation 5-HT3 antagonists.
Approved indications
- Chemotherapy-induced nausea and vomiting (CINV) prevention
- Post-operative nausea and vomiting (PONV) prevention
Common side effects
- Headache
- Constipation
- Diarrhea
- Dizziness
- Fatigue
Key clinical trials
- A Comparison Between Palonosetron Versus Granisetron as PONV Prophylaxis in Scoliotic Patients Undergoing Spine Surgery (PHASE4)
- Palonosetron Versus Ondansetron for PONV Prevention in Patients Undergoing ERCP (PHASE4)
- Post-Operative Nausea and Vomiting in Children Submitted to Strabismus Surgery (PHASE3)
- Comparison of Palonosetron Versus Combination of Palonosetron and Dexamethasone for Preventing Postoperative Vomiting in Patients Receiving Fentanyl by Patient-controlled Analgesia After Minor Orthopedic Surgery (NA)
- Comparison of TIVA (Total Intravenous Anesthesia) and TIVA Plus Palonosetron in Preventing Postoperative Nausea and Vomiting (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Palonosetron (Group P) CI brief — competitive landscape report
- Palonosetron (Group P) updates RSS · CI watch RSS
- University of Malaya portfolio CI